CLGN Stock Overview
CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, and Europe.
CollPlant Biotechnologies Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$9.99|
|52 Week High||US$23.00|
|52 Week Low||US$6.51|
|1 Month Change||15.49%|
|3 Month Change||9.30%|
|1 Year Change||-44.62%|
|3 Year Change||177.50%|
|5 Year Change||39.72%|
|Change since IPO||-45.90%|
Recent News & Updates
We Think CollPlant Biotechnologies (NASDAQ:CLGN) Can Afford To Drive Business Growth
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
|CLGN||US Biotechs||US Market|
Return vs Industry: CLGN underperformed the US Biotechs industry which returned -21.7% over the past year.
Return vs Market: CLGN underperformed the US Market which returned -10.2% over the past year.
|CLGN Average Weekly Movement||10.3%|
|Biotechs Industry Average Movement||12.6%|
|Market Average Movement||7.7%|
|10% most volatile stocks in US Market||16.9%|
|10% least volatile stocks in US Market||3.2%|
Stable Share Price: CLGN is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 10% a week.
Volatility Over Time: CLGN's weekly volatility (10%) has been stable over the past year.
About the Company
CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, and Europe. Its products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology. The company’s products include BioInks for 3D printing of tissues and organs; dermal filler and soft tissue fillers for treating wrinkles; 3D Bioprinted breast implants for regeneration of breast tissue; injectable implants to promote breast tissue regeneration; 3D bioprinted regenerative soft tissue matrix; VergenixSTR, a soft tissue repair matrix intended for the treatment of tendinopathy; and VergenixFG, an advanced wound care product for the treatment of deep surgical incisions and wounds, including diabetic ulcers, venous and pressure ulcers, burns, bedsores, and other chronic wounds.
CollPlant Biotechnologies Fundamentals Summary
|CLGN fundamental statistics|
Is CLGN overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|CLGN income statement (TTM)|
|Cost of Revenue||US$1.15m|
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
|Earnings per share (EPS)||-1.24|
|Net Profit Margin||-1,138.94%|
How did CLGN perform over the long term?See historical performance and comparison
Is CLGN undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 1/6
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for CLGN?
Other financial metrics that can be useful for relative valuation.
|What is CLGN's n/a Ratio?|
Price to Book Ratio vs Peers
How does CLGN's PB Ratio compare to its peers?
|CLGN PB Ratio vs Peers|
|Company||PB||Estimated Growth||Market Cap|
FBIO Fortress Biotech
LPTX Leap Therapeutics
ORTX Orchard Therapeutics
FENC Fennec Pharmaceuticals
CLGN CollPlant Biotechnologies
Price-To-Book vs Peers: CLGN is good value based on its Price-To-Book Ratio (2.6x) compared to the peer average (6.2x).
Price to Earnings Ratio vs Industry
How does CLGN's PE Ratio compare vs other companies in the US Biotechs Industry?
Price-To-Book vs Industry: CLGN is expensive based on its Price-To-Book Ratio (2.6x) compared to the US Biotechs industry average (1.9x)
Price to Book Ratio vs Fair Ratio
What is CLGN's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PB Ratio||2.6x|
|Fair PB Ratio||n/a|
Price-To-Book vs Fair Ratio: Insufficient data to calculate CLGN's Price-To-Book Fair Ratio for valuation analysis.
Share Price vs Fair Value
What is the Fair Price of CLGN when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate CLGN's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate CLGN's fair value for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
How is CollPlant Biotechnologies forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Future Growth Score0/6
Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as CollPlant Biotechnologies has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Discover growth companies
- Examine CollPlant Biotechnologies's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
How has CollPlant Biotechnologies performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: CLGN is currently unprofitable.
Growing Profit Margin: CLGN is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: CLGN is unprofitable, but has reduced losses over the past 5 years at a rate of 13.7% per year.
Accelerating Growth: Unable to compare CLGN's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CLGN is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (24.5%).
Return on Equity
High ROE: CLGN has a negative Return on Equity (-31.82%), as it is currently unprofitable.
Discover strong past performing companies
How is CollPlant Biotechnologies's financial position?
Financial Health Score6/6
Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: CLGN's short term assets ($42.6M) exceed its short term liabilities ($2.6M).
Long Term Liabilities: CLGN's short term assets ($42.6M) exceed its long term liabilities ($2.9M).
Debt to Equity History and Analysis
Debt Level: CLGN is debt free.
Reducing Debt: CLGN had no debt 5 years ago.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: CLGN has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: CLGN has sufficient cash runway for 2.7 years if free cash flow continues to grow at historical rates of 13.3% each year.
Discover healthy companies
What is CollPlant Biotechnologies's current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Cash Flow Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate CLGN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate CLGN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if CLGN's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if CLGN's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as CLGN has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Yehiel Tal (70 yo)
Mr. Yehiel Tal has been the Chief Executive Officer of CollPlant Biotechnologies Ltd. (formerly known as CollPlant Holdings Ltd.) since January 2010 and also serves as its Director since 2022. Mr. Tal Co-f...
CEO Compensation Analysis
Compensation vs Market: Yehiel's total compensation ($USD1.20M) is above average for companies of similar size in the US market ($USD759.98K).
Compensation vs Earnings: Yehiel's compensation has increased whilst the company is unprofitable.
Experienced Management: CLGN's management team is seasoned and experienced (8.7 years average tenure).
Experienced Board: CLGN's board of directors are considered experienced (4.2 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 11.8%.
CollPlant Biotechnologies Ltd.'s employee growth, exchange listings and data sources
- Name: CollPlant Biotechnologies Ltd.
- Ticker: CLGN
- Exchange: NasdaqGM
- Founded: 2004
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: US$110.754m
- Shares outstanding: 11.09m
- Website: https://www.collplant.com
Number of Employees
- CollPlant Biotechnologies Ltd.
- Weizmann Science Park
- 4 Oppenheimer
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/08/15 00:00|
|End of Day Share Price||2022/08/15 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.